Matt Kirchmann

As Senior Director at KMC Health Care, Matt Kirchmann brings a wealth of expertise in navigating the complex landscape of pharmaceutical market access and health technology assessment. His current role involves leading strategic initiatives related to PBAC, MSAC, and PHARMAC submissions, ensuring that innovative medical technologies and pharmaceuticals meet rigorous evaluation standards for reimbursement and funding. Matt’s deep understanding of economic modelling—particularly cost-effectiveness analyses and QALY calculations—enables his team to develop compelling, evidence-based submissions that effectively demonstrate the value of new medications within Australia’s healthcare system.

In addition to his proficiency in economic modelling, Matt oversees market viability assessments and forecasting, leveraging advanced techniques such as Monte-Carlo simulations to predict market uptake and long-term sustainability. His broad range of specialised skills in market analysis, commercialisation strategies, and strategic assessments ensures that KMC Health Care’s clients are well-positioned for successful market entry and reimbursement negotiations. Matt’s background as a solicitor and economist, combined with his academic experience lecturing at Monash University, provides him with a unique perspective on the legal, economic, and policy dimensions of health technology assessment.

His leadership at KMC Health Care emphasizes a collaborative approach, integrating rigorous quantitative analysis with strategic insights to optimize market access pathways. Whether managing complex submissions or conducting comprehensive market forecasts, Matt’s expertise ensures that clients receive tailored, innovative solutions that align with evolving regulatory and funding landscapes in the Australian healthcare sector.